OverviewShare April 1, 2026 Evolving Standards in EGFR-Mutated Non–Small Cell Lung Cancer – Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated NSCLC. Share Share Share Related Posts How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC March 26, 2026 Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC March 6, 2026 How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC March 6, 2026 AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC February 27, 2026 Tags:1L Treatment Strategies2L Treatment StrategiesVideoWinter Lung
